|Previous Section||Index||Home Page|
Rosie Cooper: To ask the Secretary of State for Health how many people worked in the Cheshire and Merseyside strategic health authority, including Southport and Ormskirk hospital trust; and what the staff costs were (a) in October and (b) at its inception. 
Mr. Byrne: The information requested on staff costs is not held centrally. Information on all national health service staff by selected group, for Cheshire and Merseyside strategic health authority by organisation, as at 30 September 2002 and 30 September 2004 has been placed in the Library.
Mr. Burstow: To ask the Secretary of State for Health on what basis she exercises her discretion to release information covered by commercial confidentiality for reasons of public accountability; and if she will list the occasions on which she has exercised this discretion in each of the last five years. 
Jane Kennedy: In considering any decision to disclose confidential information the commercial sensitivity of that information is assessed on a case by case basis at the time the request for disclosure is made, against the criteria set out in the Freedom of Information Act (2000). The Freedom of Information Act 2000 became effective on 1 January 2005.
Mike Penning: To ask the Secretary of State for Health if she will list the 10 highest-paid employees in her Department; what the (a) job title and (b) salary including bonuses is of each; and whether the individual concerned is (i) a civil servant and (ii) a contractor in each case. 
|Job title||Status||Total salary including bonus|
|Director General of NHS IT(39)||Civil Servant||280285|
|Permanent Secretary||Civil Servant||225230|
|Commercial Director(39)||Fixed Term Appointment||220225|
|Group Director of Health and Social Care Services Delivery and Department of Health Board Member||Civil Servant||190195|
|Chief Medical Officer||Civil Servant||180185|
|Director of Programmes and Performance||Civil Servant||170175|
|Director of Strategy||Civil Servant||150155|
|Director of Access||Civil Servant||145150|
|Director of Health Partnerships||Civil Servant||145150|
|Project LeadWhite Paper||Civil Servant||140145|
(3) what assessment has been made of the safety of NovoRapid for use in children; and what assessment she has made of the post-marketing data available in this respect. 
All new drugs applications, including insulins such as Novorapid are evaluated by the commission on human medicines (CHM), formerly the committee on safety of medicines (CSM) which advises the Licensing Authority as to whether a marketing
29 Nov 2005 : Column 401W
authorisation should be granted. The applicant includes, in their submission, results of clinical trials conducted in the proposed indication for which the licence is sought. The first marketing authorisation for the recombinant human insulin was granted to NovoNordisk on 9 June 1982. This application was considered by the expert biologicals sub-committee of the CSM, in March 1982 and subsequently by the main committee. The application for a new drug substance such as recombinant human insulin would have been scientifically and medically reviewed to ensure it satisfied the criteria for safety, quality and efficacy. Medicinal products, including human or animal insulin, will not be granted a marketing authorisation unless supporting data have been provided to demonstrate that the quality, safety and efficacy are satisfactory for the intended use. The type of clinical development programme, clinical trial data, that should support the registration of new medicinal products for the indication treatment of diabetes mellitus is detailed in European guidance documents, for example, notes for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. CPMP/EWP/1080/00. These are read in conjunction with other pertinent European and International (ICH) clinical guidelines. The marketing authorisation applications are evaluated by the CSM before they are granted.
Data from clinical trials submitted at the time of licensing examined the safety and efficacy of the human insulin analogues (insulin glargine, insulin aspart, insulin detemir, insulin lispro and insulin gluisine) in diabetic patients treated for up to 12 months. A summary of the available data submitted in support of the licence applications for many of the insulin analogues is made publicly available in the form of a European Public Assessment Report.
The longer term safety of the use of human insulin analogues in routine clinical practice is monitored by the Medicines and Healthcare products Regulatory Agency (MHRA). Any possible new safety issue to emerge is evaluated and, if necessary, product information for prescribers and patients is updated to reflect the new data.
As with all medicines, reports of suspected adverse drug reactions (ADRs) to insulin analogues are collected by MHRA and CHM through the spontaneous reporting scheme, the Yellow Card scheme. A summary of the ADRs that have been received in association with a medicine, including insulin analogues, is available on the MHRA's website.
|NHS trust||Expenditure (£000)|
|200001||Blackburn, Hyndburn and Ribble Valley NHS Trust||101,488|
|Burnley Healthcare NHS Trust||113,521|
|200102||Blackburn, Hyndburn and Ribble Valley NHS Trust||114,282|
|Burnley Healthcare NHS Trust||125,506|
|200203||Blackburn, Hyndburn and Ribble Valley NHS Trust||116,154|
|Burnley Healthcare NHS Trust||103,577|
|200304||East Lancashire Hospitals NHS Trust||231,430|
|200405||East Lancashire Hospitals NHS Trust||255,313|
Sarah Teather: To ask the Secretary of State for Health how many people have been prosecuted under the Health Act 1999 for wrongful claims of free prescriptions in London in each year since 2000. 
Jane Kennedy: Since August 2001, a penalty charge system has been in place in respect of those falsely claiming exemption to national health service pharmaceutical charges. Since its introduction in August 2001, 160,000 penalty notices have been issued. The total amount recovered to date is £2,950,000. These figures are national and are not broken down into regions as requested. This is done through the civil courts as criminal prosecution of offenders would not be a cost-effective way of dealing with such high volume but low-value frauds.
|Next Section||Index||Home Page|